These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 20446905)

  • 41. Cytochromes P450: decision-making tools for personalized therapeutics.
    Murray M; Petrovic N
    Curr Opin Mol Ther; 2006 Dec; 8(6):480-6. PubMed ID: 17243482
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genetic polymorphism and toxicology--with emphasis on cytochrome p450.
    Johansson I; Ingelman-Sundberg M
    Toxicol Sci; 2011 Mar; 120(1):1-13. PubMed ID: 21149643
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology.
    Prandota J
    Am J Ther; 2005; 12(3):254-61. PubMed ID: 15891270
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics.
    Forrester LM; Henderson CJ; Glancey MJ; Back DJ; Park BK; Ball SE; Kitteringham NR; McLaren AW; Miles JS; Skett P
    Biochem J; 1992 Jan; 281 ( Pt 2)(Pt 2):359-68. PubMed ID: 1736885
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.
    Wilkinson GR
    J Pharmacokinet Biopharm; 1996 Oct; 24(5):475-90. PubMed ID: 9131486
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Update: genetic polymorphism of drug metabolizing enzymes in humans.
    Tanaka E
    J Clin Pharm Ther; 1999 Oct; 24(5):323-9. PubMed ID: 10583694
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes (review).
    Murray M
    Int J Mol Med; 1999 Mar; 3(3):227-38. PubMed ID: 10028046
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Clinical significance of cytochrome P450 genetic polymorphism--part I. Enzymatic system of cytochrome P450 and cytochrome P450 1A2].
    Duricová J; Grundmann M
    Ceska Slov Farm; 2011 Jun; 60(3):110-5. PubMed ID: 21838140
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics.
    Brosen K
    Clin Pharmacokinet; 1990 Mar; 18(3):220-39. PubMed ID: 2182263
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes.
    Ingelman-Sundberg M
    Mutat Res; 2001 Oct; 482(1-2):11-9. PubMed ID: 11535244
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Toxicology and pharmacogenetics].
    Dalhoff KP; Poulsen HE
    Ugeskr Laeger; 2005 May; 167(20):2170-2. PubMed ID: 15987076
    [No Abstract]   [Full Text] [Related]  

  • 52. Cytochrome p450 part 2: what nurses need to know about the cytochrome p450 family systems.
    Krau SD
    Nurs Clin North Am; 2013 Dec; 48(4):681-96. PubMed ID: 24295195
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions--a pilot study.
    Egger T; Dormann H; Ahne G; Pahl A; Runge U; Azaz-Livshits T; Neubert A; Criegee-Rieck M; Gassmann KG; Brune K
    Drugs Aging; 2005; 22(3):265-72. PubMed ID: 15813658
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Challenges in exploring the cytochrome P450 system as a source of variation in canine drug pharmacokinetics.
    Martinez MN; Antonovic L; Court M; Dacasto M; Fink-Gremmels J; Kukanich B; Locuson C; Mealey K; Myers MJ; Trepanier L
    Drug Metab Rev; 2013 May; 45(2):218-30. PubMed ID: 23432217
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of P450 Oxidoreductase Polymorphisms on the Metabolic Activities of Ten Cytochrome P450s Varied by Polymorphic CYP Genotypes in Human Liver Microsomes.
    Fang Y; Gao N; Tian X; Zhou J; Zhang HF; Gao J; He XP; Wen Q; Jia LJ; Jin H; Qiao HL
    Cell Physiol Biochem; 2018; 47(4):1604-1616. PubMed ID: 29949783
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Electrochemically driven drug metabolism by membranes containing human cytochrome P450.
    Mie Y; Suzuki M; Komatsu Y
    J Am Chem Soc; 2009 May; 131(19):6646-7. PubMed ID: 19402636
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association of polymorphisms in the cytochrome P450 (CYP) 2C19 and 2C18 genes in Japanese epileptic patients.
    Mamiya K; Ieiri I; Miyahara S; Imai J; Furuumi H; Fukumaki Y; Ninomiya H; Tashiro N; Yamada H; Higuchi S
    Pharmacogenetics; 1998 Feb; 8(1):87-90. PubMed ID: 9511186
    [No Abstract]   [Full Text] [Related]  

  • 58. Combining in silico protein stability calculations with structure-function relationships to explore the effect of polymorphic variation on cytochrome P450 drug metabolism.
    Arendse L; Blundell TL; Blackburn J
    Curr Drug Metab; 2013 Sep; 14(7):745-63. PubMed ID: 23826828
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacogenetics of drug metabolising enzymes: importance for personalised medicine.
    Oscarson M
    Clin Chem Lab Med; 2003 Apr; 41(4):573-80. PubMed ID: 12747605
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Gerhard Zbinden Memorial Lecture. Genetic polymorphism of drug metabolizing enzymes. Implications for toxicity of drugs and other xenobiotics.
    Ingelman-Sundberg M
    Arch Toxicol Suppl; 1997; 19():3-13. PubMed ID: 9079190
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.